Decoy Therapeutics Inc
DCOY
Closed
$0.92
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
Decoy Therapeutics, Inc. operates as a preclinical-stage biotechnology company. The company is headquartered in Houston, Texas and currently employs 11 full-time employees. The company went IPO on 2015-01-29. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.
Key stats
Open
$0.97
Volume
49.69K
Market cap
$2.31M
Prev. close
$0.92
Impl / hst vl
-
Open interest
$0.00
$0.90
Day’s Range
$1.00
$0.51
52W Range
$13.51
Valuation
38
Valuation score
Overvalued
P/E
-
P/S
-
P/B
0.54
Current ratio
1.83
Debt / Equity
-1.92
ROE
-315.23%
Gross margin
-
Income growth
6.71%
FCF growth
-6.75
Analysts estimates
Consensus rating
Strong buy
The average rating from top 3 analysts indicates that stock may significantly outperform the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$3.06
The top 3 analysts forecasts that 12-month price may increase by 232.61%, with a low of $3.03 and a high of $3.15
$3.03
Low
$3.06
Avg
$3.15
High
Current price
Earnings
Q2 ‘26 revenue
$227.60K
Q2 ‘26 net income
-$2.37M
Revenue
Net income
Previous EPS
-Estimate EPS
-$2.64
Actual EPS
Estimate EPS
Explore the Healthcare sector
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply